ACP
UTHR icon

Aviance Capital Partners’s United Therapeutics UTHR Stock Holding History

Aviance Capital Partners’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-5,763
Closed -$680K – 218
2016
Q3 		$680K Buy
5,763
+271
+5% +$32.6K 0.24% 109
2016
Q2 		$582K Buy
+5,492
New +$613K 0.21% 114

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return

Aviance Capital Partners's UTHR Position: Q4 2016 in Review

Aviance Capital Partners sold out of United Therapeutics (UTHR) in Q4 2016, closing a stake of 5,763 shares — an estimated $680K sold.

Aviance Capital Partners first reported a position in UTHR in Q2 2016 and held it in 2 quarters. The position peaked at $680K in Q3 2016. 406 funds tracked by Wall St. Rank hold UTHR as of Q4 2016.

  • Aviance Capital Partners reported no remaining United Therapeutics position as of Q4 2016 after selling out during the quarter.
  • Aviance Capital Partners sold 5,763 United Therapeutics shares in Q4 2016, an estimated $680K.
  • Aviance Capital Partners first reported a position in United Therapeutics in Q2 2016 and held it in 2 quarters.
  • Aviance Capital Partners's United Therapeutics position peaked at $680K in Q3 2016.
  • 406 funds tracked by Wall St. Rank held United Therapeutics as of Q4 2016.

Based on Aviance Capital Partners's 13F filing for Q4 2016, filed 17 Jan 2017.